AMANDA CANAVAN: Open Payments
NPI 1154307759 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$320 in 13 payments from 7 companies in 2025. Trend: 2023 $269 · 2024 $242 · 2025 $320
Food & beverage: $320
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 5 | $86 |
| BioCryst US Sales Co., LLC | 2 | $82 |
| Optinose US, Inc. | 2 | $33 |
| GENZYME CORPORATION | 1 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Incyte Corporation | 1 | $29 |
| Genentech USA, Inc. | 1 | $27 |
Products named: ORLADEYO, TRELEGY ELLIPTA, NUCALA, Xhance, WAYRILZ, HYQVIA, OPZELURA, Xolair.
Industry payments across DE — which companies pay providers there.
